Growth hormone (GH) therapy, a cornerstone of PWS management, substantially improves linear growth, body composition, and muscle strength, yet its relationship with scoliosis onset and progression remains a clinical challenge due to the potential for accelerated growth during critical developmental windows, which may unmask or exacerbate underlying spinal instability. The gene discussed is GH1; the disease is scoliosis.